Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Biotech Clinical Trials

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab

Tuba Khan May 7, 2021

Shots: The P-III POSEIDON study involves assessing Imfinzi + platinum-based CT or Imfinzi + Tremelimumab + CT vs CT as monothx as a 1L treatment in patients with mNSCLC The study demonstrated improvement in OS and combination also showed improvement in PFS, as previously reported in Oct 2019. In a previous analysis, patients treated with […]Read More

Pharma

Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for

Tuba Khan May 7, 2021

Shots: The collaboration will evaluate Fusion’s FPI-1434 + Merck’s Keytruda in patients with solid tumors expressing IGF-1R. Fusion will sponsor the study and Merck will supply Keytruda The companies plan to initiate a P-I/II trial to evaluate the safety, tolerability, and PK of combination therapy and is expected in ~6 to 9 mos. upon achieving […]Read More

MedTech

BMS Signs a Research Collaboration with DarwinHealth to Discover Novel

Tuba Khan May 7, 2021

Shots: DarwinHealth will receive an upfront and eligible to receive as a commercial milestone, as part of the NCTI collaboration The focus of the collaboration is to identify NCTs across tumor subtypes for different cancer types by using quantitative systems biology-based algorithms, databases, and technologies and leads to the development of drugs with multi-subtype indications […]Read More

Pharma

BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 +

Tuba Khan May 7, 2021

Shots: BeiGene and Asieris collaborate to evaluate the safety and efficacy of APL-1202 + tislelizumab as neoadjuvant therapy in patients with MIBC. APL-1202 has been approved to treat patients with locally advanced or metastatic UC and high expression of PD-L1 who failed to receive platinum-based CT Asieris plans to submit INDs in China and the […]Read More

Biotech

AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific

Tuba Khan May 7, 2021

Shots: AbCellera will receive equity and research fees and is eligible to receive milestone along with royalties based on the development and commercialization of Abs Angios gets the rights to develop and commercialize therapeutic products resulting from the collaboration AbCellera will use an AI-powered platform to generate panels of Abs for up to three Angios-selected […]Read More

Regulatory

Merck and Eisai Receive the US FDA‘s Priority Review for

Tuba Khan May 7, 2021

Shots: The 1st sNDA and sBLA is based on results from the P-III CLEAR Study evaluating Lenvima + Keytruda or in combination with everolimus vs sunitinib in a ratio (1:1:1) in 1,069 patients with advanced RCC, demonstrated improved PFS, OS, and ORR The 2nd application is based on results from the P-III KEYNOTE-775/Study 309 trial […]Read More

Insights+

Insights+ Key Biosimilars Events of April 2021

Tuba Khan May 6, 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC’s approval for […]Read More

Regulatory

Amgen Reports the US FDA’s Acceptance of sNDA for Review

Tuba Khan May 6, 2021

Shots: The acceptance is based on a P-III ADVANCE trial assessing the efficacy of Otezla (30 mg, bid) vs PBO in 595 patients in a ratio (1:1) with mild-to-moderate plaque psoriasis for the first 16wks. All patients then received Otezla during an OLE phase through week 32. Results: @16wks., improvement in its 1EPs of sPGA […]Read More

COVID-19

Roche’s Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat

Tuba Khan May 6, 2021

Shots: The CDSCO has granted a EUA for Roche’s casirivimab and imdevimab to treat COVID-19 in India. The approval of the Ab cocktail was based on the data that has been filed for the EUA in the US and the CHMP’s opinion in the EU Roche will import the globally manufactured product batches to India […]Read More

Biotech

Sanofi Signs a Three-Year Collaboration with Stanford Medicine to Accelerate

Tuba Khan May 6, 2021

Shots: Sanofi and Stanford Medicine collaborated to initiate three “deep-dive” research projects focusing on autoimmune diseases and inflammatory conditions The partners will organize a joint committee to fund three programs in a year with an annual research forum held by Sanofi for researchers from both organizations to further exchange ideas and discuss collaborative research projects […]Read More

Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + Keytruda (pembrolizumab) to Treat Solid Tumors Expressing IGF-1R

BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific Antibodies for the Treatment of Diabetic Retinopathy

Amgen Launches Amgevita (biosimilar, adalimumab) for the Treatment of Multiple Chronic Inflammatory Diseases in Canada

Sandoz Initiates Patient Enrolment of Proposed Biosimilar Aflibercept in P-III MYLIGHT Study for Neovascular Age-Related Macular Degeneration

Roche’s Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat COVID-19 in India

Celltrion Reports Results of Regdanvimab (CT-P59) in Pre-Clinical Study Against the South African Variant (B.1.351)

Merck and Eisai Receive the US FDA‘s Priority Review for Keytruda (pembrolizumab) + Lenvima (lenvatinib) to Treat Advanced Renal Cell Carcinoma and Endometrial Carcinoma

Amgen Reports the US FDA’s Acceptance of sNDA for Review of Otezla (apremilast) to Treat Mild-To-Moderate Plaque Psoriasis

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

AbCellera to Initiate Clinical Trial of LY-CoV1404 Against Viral Variants of COVID 19

Tuba Khan

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab

Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for

BMS Signs a Research Collaboration with DarwinHealth to Discover Novel

BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 +

AbCellera Signs a Multi-Target Collaboration with Amgen to Develop Bispecific

Merck and Eisai Receive the US FDA‘s Priority Review for

Insights+ Key Biosimilars Events of April 2021

Amgen Reports the US FDA’s Acceptance of sNDA for Review

Roche’s Ab Cocktail (Casirivimab and Imdevimab) Receives EUA to Treat

Sanofi Signs a Three-Year Collaboration with Stanford Medicine to Accelerate

Latest Posts

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + Keytruda (pembrolizumab) to Treat Solid Tumors Expressing IGF-1R

BMS Signs a Research Collaboration with DarwinHealth to Discover Novel Cancer Target Initiative

BeiGene and Asieris Enter into Clinical Collaboration for APL-1202 + Tislelizumab to Treat Muscle Invasive Bladder Cancer

Tuba Khan

Latest Posts

Categories

Related Topics